PAR 6.67% 24.0¢ paradigm biopharmaceuticals limited..

Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-317

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 353 Posts.
    lightbulb Created with Sketch. 399
    Keen to hear your thoughts on what you and others considered "less than stellar" about the Phase II results?
    Want to get an understanding of what investors were actually expecting from the results.

    Was it merely the p values that everyone baulked at?
    Was it the lack of MRI pictures being included?
    Was it the title that still only suggested potential for DMOAD and didn't claim it?

    I personally didn't think they were bad once I learned how a p value works, and that the study size was too small to expect significance.

    Very interested to hear what peoples personal expectations were, without any hyperbole or emotions, just what people wanted to read.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
24.0¢
Change
0.015(6.67%)
Mkt cap ! $81.36M
Open High Low Value Volume
22.5¢ 24.0¢ 22.5¢ $173.6K 743.6K

Buyers (Bids)

No. Vol. Price($)
8 99346 22.5¢
 

Sellers (Offers)

Price($) Vol. No.
24.0¢ 131244 5
View Market Depth
Last trade - 16.10pm 13/11/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.